Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: A multi-tumour,multi-institutional phase II study

Patrick Schöffski, B. Besse, T. Gauler, M. J A de Jonge, G. Scambia, A. Santoro, C. Davite, M. G. Jannuzzo, A. Petroccione, J. P. Delord

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: A multi-tumour,multi-institutional phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences